Design and Preparation of Pharmaceutical Solid Dosage Forms of Benznidazole for the Treatment of Chagas Disease

Authors

  • Sonia Tarragona Fundación Mundo Sano, CABA
  • Claudio Salomón Departamento Farmacia, Área Técnica Farmacéutica, Facultad de Ciencias Bioquímicas y Farmacéuticas, Universidad Nacional de Rosario
  • Álvaro Jiménez-Kairuz Departamento Farmacia, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba
  • María Lamas Departamento Farmacia, Área Técnica Farmacéutica, Facultad de Ciencias Bioquímicas y Farmacéuticas, Universidad Nacional de Rosario
  • Silvina Orlandi Departamento Farmacia, Área Técnica Farmacéutica, Facultad de Ciencias Bioquímicas y Farmacéuticas, Universidad Nacional de Rosario
  • Darío Leonardi Departamento Farmacia, Área Técnica Farmacéutica, Facultad de Ciencias Bioquímicas y Farmacéuticas, Universidad Nacional de Rosario
  • Norma Maggia Departamento Farmacia, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba
  • Alejandro Paredes Departamento Farmacia, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba
  • Carolina Romañuk Departamento Farmacia, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba
  • Mónica García Departamento Farmacia, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba

Keywords:

Chagas disease, Antiparasitics, Benznidazole, Medicines, New formulations

Abstract

INTRODUCTION: In Argentina, benznidazole is the drug of choice for the etiological treatment of Chagas disease. Since it was launched (more than 40 years ago), there are only 100 mg tablets available; the development included neither new pharmaceutical forms improving efficacy and safety, nor a pediatric dosage option. OBJECTIVES: To develop pharmaceutical forms of benznidazole with pharmacotherapeutic advantages. METHODS: Preformulation and design of new formulations of benznidazole, with physicochemical characterization and selection of the most favorable formulations. Due to the discontinuity in the production of the active ingredient benznidazole, a specific methodology was developed in order to obtain it from the only commercially available alternative. RESULTS: New benznidazole tablet formulations were obtained (50 and 100 mg), with a rapid dissolution of the reference product, as well as chewable formulations of 50 mg as sugar hydrogels featuring an effective taste masking. All formulations passed the evaluation tests for pharmacotechnical and biopharmaceutical properties, outperforming the reference profiles. CONCLUSIONS: New fast-dissolving pharmaceutical dosage forms of benznidazole were developed, which could improve the etiological treatment of the disease (especially in the pediatric field) and become a proper tool for its commercial exploitation.

Downloads

Download data is not yet available.

Published

03-06-2013

How to Cite

Tarragona, S. ., Salomón, C. ., Jiménez-Kairuz , Álvaro ., Lamas, M. ., Orlandi , S. ., Leonardi , D. ., … García, M. (2013). Design and Preparation of Pharmaceutical Solid Dosage Forms of Benznidazole for the Treatment of Chagas Disease. Revista Argentina De Salud Pública, 4(15), 6–13. Retrieved from https://rasp.msal.gov.ar/index.php/rasp/article/view/301